Overview

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment

Status:
Recruiting
Trial end date:
2024-02-13
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetic characteristics of pyroglutamate rongliflozin capsules in type 2 diabetic subjects with normal renal function and mild to moderate renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.